Potential treatment for brain cancer as drug shrinks tumours

August 14, 2017
Potential treatment for brain cancer as drug shrinks tumours
L-R: Dr Amanda Millar, Dr Laura Genovesi and Professor Brandon Wainwright. Credit: University of Queensland

An international team of researchers has found a drug previously approved to treat breast cancer could also be used to shrink medulloblastoma, a common form of childhood brain tumour.

The discovery, made by The University of Queensland's Institute for Molecular Bioscience and the Fred Hutchinson Cancer Research Center in Seattle, has led to a clinical trial using the drug palbociclib to treat children with , the most common malignant brain found in children.

UQ's Professor Brandon Wainwright said were the most common cause of cancer death in infants, children and adolescents – and even survivors can end up with significant long-term side effects from existing treatments.

"Clearly, we need new therapies that increase survival of young patients and reduce the side effects they suffer, such as delays in brain development, growth problems and increased risk of other cancers," Professor Wainwright said.

Fellow UQ researcher Dr Laura Genovesi examined the genetic code of medulloblastoma to predict whether these tumours may respond to already-approved drugs.

"This analysis led us to believe that palbociclib, an oral approved in 2015 for the treatment of , would be effective against medulloblastoma," Dr Genovesi said.

"We expected that palbociclib would arrest the growth of medulloblastoma, but we were stunned to find that it went a step further and actually shrank the tumours to a size where survival is possible."

"The finding is remarkable since the tumours were very advanced and were treated for only a short period of time and we did not use any other therapy such as chemotherapy in combination.

"Some tumours recurred once treatment with palbociclib stopped, probably due to resistant cells within the tumour.

"It means that palbociclib, or drugs like it, could be used against medulloblastoma in combination with other drugs to treat resistant cells.

"If the clinical trial is successful, it would represent a major step forward to taking this research from the genome to the clinic."

The study is published in the journal Clinical Cancer Research.

Explore further: Study reveals genes behind brain tumours

More information: Michelle L Cook Sangar et al. Inhibition of CDK4/6 by Palbociclib Significantly Extends Survival in Medulloblastoma Patient-Derived Xenograft Mouse Models, Clinical Cancer Research (2017). DOI: 10.1158/1078-0432.CCR-16-2943

Related Stories

Study reveals genes behind brain tumours

October 31, 2013
A team of researchers has pinpointed a handful of genes that could drive the formation of medulloblastoma, the most aggressive and frequent form of brain tumour found in children.

New insight into life-threatening childhood brain cancer

May 22, 2017
The most common type of malignant childhood brain cancer has been identified as seven separate conditions each needing a different treatment, new research has revealed.

Improving the survival rates of childhood brain tumours: Translating Discoveries

July 13, 2017
The future of children with brain tumours is very promising. To do nothing is to ignore the very real possibility of a treatment and cure. It is the time now to accelerate clinical and laboratory research in childhood brain ...

Stem cells may speed up screening of drugs for rare cancers

August 2, 2016
Researchers at the Johns Hopkins Kimmel Cancer Center say they have developed a system that uses transformed human stem cells to speed up screening of existing drugs that might work against rare brain and other cancers.

Scientists map out how childhood brain tumors relapse

December 18, 2014
Researchers have discovered the unique genetic paths that the childhood brain tumour medulloblastoma follows when the disease comes back, according to research published in Cancer Cell today.

Study shows biomarkers can predict which ER-positive breast cancer patients respond best to first-line therapy

June 27, 2017
Two challenges in treating patients with estrogen-positive breast cancer (ER+) have been an inability to predict who will respond to standard therapies and adverse events leading to therapy discontinuation. A study at The ...

Recommended for you

Researchers discover a new target for 'triple-negative' breast cancer

November 20, 2017
So-called "triple-negative" breast cancer is a particularly aggressive and difficult-to-treat form. It accounts for only about 10 percent of breast cancer cases, but is responsible for about 25 percent of breast cancer fatalities.

Study reveals new mechanism used by cancer cells to disarm attacking immune cells

November 20, 2017
A new study by researchers at The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute (OSUCCC - James) identifies a substance released by pancreatic cancer cells that protects ...

Clinical trial suggests new cell therapy for relapsed leukemia patients

November 20, 2017
A significant proportion of children and young adults with treatment-resistant B-cell leukemia who participated in a small study achieved remission with the help of a new form of gene therapy, according to researchers at ...

Cell-weighing method could help doctors choose cancer drugs

November 20, 2017
Doctors have many drugs available to treat multiple myeloma, a type of blood cancer. However, there is no way to predict, by genetic markers or other means, how a patient will respond to a particular drug. This can lead to ...

Lung cancer triggers pulmonary hypertension

November 17, 2017
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart ...

Researchers discover an Achilles heel in a lethal leukemia

November 16, 2017
Researchers have discovered how a linkage between two proteins in acute myeloid leukemia enables cancer cells to resist chemotherapy and showed that disrupting the linkage could render the cells vulnerable to treatment. St. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.